Skip to main content
. 2017 Feb 11;8(15):24892–24901. doi: 10.18632/oncotarget.15279

Figure 4. The value of serum MIC-1 in the prediction of CRC prognosis.

Figure 4

Tumor-specific survival curves were prepared and analyzed between two divided groups according to the median levels of serum MIC-1 in patients before treatment (average, 43 months; range, 9–80 months; n=94). Patients with higher serum MIC-1 had a trend to poorer tumor-specific survival (median survival time: 34 vs 50 months, P<0.0001).